Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

In 30 seconds

This Phase I clinical trial evaluated the safety of dordaviprone maintenance therapy after allogeneic hematopoietic cell transplantation in 20 adults with high-risk acute myeloid leukemia (AML) or myelodysplastic neoplasm (MDS). The study found no dose-limiting toxicities, and at 2 years, relapse-free survival was 60% and overall survival was 70%.

Key findings

• No dose-limiting toxicities or graft failures were observed during the trial.
• Grade ≥3 adverse events occurred in 45% of patients, with 15% deemed related to treatment.
• At 2 years, relapse-free survival was 60% and overall survival was 70%.

Why it matters

The findings suggest that dordaviprone may be a safe maintenance therapy option for patients with high-risk AML and MDS post-transplant, potentially improving survival outcomes in this vulnerable population.